COMPANY

Deep Apple Therapeutics

Keywords: small molecule

Location: New York, NY · source · Oct 15, 2026

Profile checked Oct 10, 2026

Raises and deals from press releases

Deal Novo Nordisk deal · up to $812M total · announced Jun 11, 2025 Company release ↗
Source quote
- Jun 11, 2025 · Company release ↗
  “Partnership aims to develop first-in-class, small molecule therapeutics directed at a novel non-incretin GPCR target for cardiometabolic diseases Deep Apple is eligible to receive up to $812 million, including an upfront payment”

From the company’s own releases; this list is partial. All raises and deals

Jun 11, 2025 Partnership Partnership / licensing: upfront not published; deal value up to $812M (kept separate from upfront), announced Jun 11, 2025. Source: company's own press page. source ↗

Last 2 years.

Jun 11, 2025 Partnership / licensing: upfront not published; deal value up to $812M (kept separate from upfront), announced Jun 11, 2025. Source: company's own press page. source ↗

LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.

LinkedIn page linked from the company's own site: source · seen 2026-10-04